Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26961745 | 0.89 | PDE4B (0.40) | PDE4BMCHR1KCNH2GPR119GAA | |
| SCHEMBL31143206 | 0.85 | SRC (0.37) | SRCMCHR1KCNH2XIAPGAA | |
| SCHEMBL26962172 | 0.84 | SRC (0.36) | PDE4BSRCXIAPGAANPY1R | |
| SCHEMBL26961737 | 0.83 | XIAP (0.36) | PDE4BSRCXIAPSMN1; SMN2NPY1R | |
| SCHEMBL26962312 | 0.83 | PDE4B (0.39) | PDE4BSRCMCHR1KCNH2GPR119 | |
| SCHEMBL26961919 | 0.82 | SRC (0.43) | PDE4BSRCXIAPGAASMN1; SMN2 | |
| SCHEMBL26961685 | 0.81 | MCHR1 (0.38) | PDE4BMCHR1KCNH2SMN1; SMN2 | |
| SCHEMBL26962039 | 0.80 | XIAP (0.36) | PDE4BSRCXIAPGPR119NPY1R | |
| SCHEMBL31375601 | 0.80 | XIAP (0.34) | PDE4BSRCXIAPNPY1R | |
| SCHEMBL29270821 | 0.77 | XIAP (0.38) | SRCXIAPSMN1; SMN2NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | PDE4B 2683/4885SRC 2202/4885MCHR1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.